Method Uses Monoterpene or Sesquiterpene to Permeabilize Blood Brain Barrier
The USPTO has published a patent application detailing a method for permeabilizing the blood-brain barrier using monoterpenes or sesquiterpenes. The application, assigned to the University of Southern California, describes a treatment for central nervous system cancers involving perillyl alcohol and CAR-T cells.
Patent Application for Dispersible Pharmaceutical Formulations
The USPTO has published patent application US20260083690A1 concerning dispersible pharmaceutical formulations of a specific chemical compound. The application details the composition and potential uses of these formulations.
Patent Application for Treating Disease with Dichlorphenamide
The USPTO has published a patent application (US20260083692A1) from Strongbridge Dublin Limited for methods of treating disease using dichlorphenamide in conjunction with an organic anion transporter-1 (OAT1) substrate. The application details methods for administering the compounds and monitoring patient response and toxicity.
Patent Application for Suppressing Reflux-Induced Protein Adducts
The USPTO has published patent application US20260083686A1, filed on November 24, 2025, by Alexander Zaika and Sergey I Dikalov. The application details methods and compounds for suppressing the accumulation of reflux-induced protein adducts.
Intranasal Pharmaceutical Composition for Migraine Treatment
The USPTO has published a patent application (US20260083693A1) for an intranasal pharmaceutical composition containing ibuprofen and ketoprofen for treating migraine and headaches. The application details a method for manufacturing preparations with a combination of these active ingredients at reduced dosages compared to oral administration.
Composition of L-leucine and fish oil for muscle health
The USPTO has published a patent application (US20260083694A1) for a composition comprising L-leucine and fish oil, intended for muscle health and the prevention of muscle mass and strength loss. The application was filed by ABIOGEN PHARMA S.P.A.
Patent Application: Composition for Mitigating Veisalgia and Nausea
The USPTO has published a patent application (US20260083695A1) for a composition designed to reduce veisalgia (hangover) symptoms and nausea. The application details an orally deliverable formulation containing dihydromyricetin, acetylcysteine, and specific antiemetics, with a filing date of September 10, 2025.
Gamma-hydroxybutyrate Formulations with Improved Pharmacokinetics
The USPTO has published a new patent application, US20260083696A1, detailing modified release formulations of gamma-hydroxybutyrate with improved dissolution and pharmacokinetic properties. The application was filed on October 1, 2025, by inventors Jordan Dubow, Claire Megret, Hervé Guillard, and Jean-François Dubuisson.
Patent Application: Composition for Controlling Aquatic Organism Infections
The USPTO has published a new patent application (US20260083697A1) from B. G. Negev Technologies and Applications Ltd. The application details a composition containing an esterified fatty acid for preventing or treating monogenean infections in aquatic organisms.
Patent Application: Synergistic Stimulation for Cystic Fibrosis Mucus Obstruction
The USPTO has published a new patent application (US20260083698A1) detailing methods for treating mucus obstruction in cystic fibrosis and other disorders. The application, filed on September 19, 2023, describes a combination therapy involving a b-adrenergic agonist or adenylate cyclase activator with a cholinergic agonist.
Patent Application for Psychoactive Medicines Treating Disorders
The USPTO has published patent application US20260083699A1 by Transcend Therapeutics, Inc. The application details psychoactive medicines, including 2C-B and cathinones, for treating psychiatric and neurological conditions. The filing date was December 4, 2025.
Patent Application for Inflammatory Condition Treatment Compositions
The USPTO has published a new patent application (US20260083701A1) for compositions and methods related to the treatment of inflammatory conditions. The application details compounds and formulations aimed at managing inflammation and associated symptoms like dryness, itching, and redness.
Patent Application: Inhalation Formulation for Treating IPF Disease
The USPTO has published a patent application (US20260083702A1) detailing an inhalation formulation for treating Idiopathic Pulmonary Fibrosis (IPF) disease. The application describes formulations using specific drugs like apremilast and roflumilast, aiming to improve bioavailability and clinical efficacy compared to oral administration.
USPTO Patent Application for Indoline Derivatives as Serotonergic Agents
The USPTO has published a patent application (US20260083703A1) for indoline derivatives intended for use as serotonergic agents. The application details potential treatments for disorders related to serotonin receptor activation, including psychosis, mental illnesses, and CNS disorders.
USPTO Patent Application for Lactation Reduction Compounds
The USPTO has published a patent application (US20260083687A1) for compounds intended for reducing lactation and improving health. The application, filed on April 14, 2023, lists specific disulfide, sulfide, trisulfide, sulfone, thiosulfinate, and thiosulfonate compounds as preferred embodiments. This represents a new patent filing, not a regulatory rule or guidance.
Skin Barrier Film System Patent Application
The USPTO has published a new patent application, US20260083684A1, for a skin barrier film system. The application details a system comprising a film layer, adhesive, impregnated treatment, and a removable layer, designed to accommodate patient physical attributes. The filing date was September 24, 2025.
Patent Application: Methods Treat/Prevent Protein Aggregation Diseases Using Sulfatase Inhibitor
The USPTO has published a new patent application (US20260083700A1) detailing methods for treating and/or preventing protein-aggregation diseases by administering a sulfatase inhibitor. The application was filed on September 26, 2025, by inventors Manuel J. Muñoz, Ángel M. Carrión, and Mercedes M. Pérez-Jiménez.
NACA Tablets Inhibit Vision Reduction in Usher Syndrome Patients
The USPTO has published a patent application (US20260083688A1) detailing compositions and methods for treating Usher syndrome associated retinitis pigmentosa using N-acetylcysteine amide (NACA) tablets. The application outlines specific dosages and claims to inhibit vision degradation and protect retinal sensitivity in patients.
Patent Application: Reversing Dexmedetomidine Sedation
The USPTO has published a patent application (US20260083689A1) detailing methods and compositions for reversing dexmedetomidine sedation using dextroamphetamine and/or lisdexamfetamine. The application was filed on October 7, 2025, by inventors Ken Solt, Oluwaseun Johnson-Akeju, and Emery N. Brown.
Gear Isle Recalls Chocolate for Undeclared Sildenafil and Tadalafil
Gear Isle is voluntarily recalling its Gold Lion and ilum chocolate products nationwide due to undeclared sildenafil and tadalafil. These ingredients can interact with prescription medications and pose a serious health risk. Consumers are advised to stop using the product and return it for a refund.
Falcon Trading Company Recalls Organic Black Beans for Pesticide Residue
Falcon Trading Company, Inc. is recalling organic black beans and related products due to the presence of pesticide residue. The recall affects all lot numbers of specific items sold in bulk. Consumers are urged to return the products for a full refund.
KAO CORPORATION patent for hair treatment agent
The USPTO has published a patent application by KAO CORPORATION for a hair treatment agent. The application, filed on May 31, 2023, details a specific formulation involving film-forming polymers and organopolysiloxanes.
Cannabis Products and Methods Patent Application
The USPTO has published a patent application (US20260083661A1) for cannabis-based products and methods, including lotions, soaps, perfumes, and teas. The application was filed on October 7, 2025, and lists Lawrence Lanier Long as the inventor.
Oxazolidinone Liposome Compositions with Improved Storage Stability
The USPTO has published a new patent application from Akagera Medicines, Inc. detailing oxazolidinone liposome compositions designed for improved storage stability. The application, filed on December 2, 2025, describes methods for manufacturing and using these compositions.
Protein Nanospheres for Treating Chemotherapy Dysfunction
The USPTO has published a patent application (US20260083683A1) for protein nanospheres designed to treat dysfunction caused by chemotherapy and immunosuppressive therapy. The application details the manufacture and use of fibrinogen-coated albumin spheres (FAS) and High-Fibrinogen Spheres (HFS) for mitigating toxic effects of cancer treatments.
High-Bioactivity Goat Colostrum Powder Preparation Method
The USPTO has published a patent application detailing a method for preparing a high-bioactivity goat colostrum composite freeze-dried powder. The invention focuses on enhancing the stability and survival rate of probiotics within the powder through encapsulation techniques.
Patent for Spray-Dried Amorphous Solid Dispersions Using Polyvinyl Alcohol
The USPTO has published a new patent application (US20260083676A1) detailing a method for preparing spray-dried amorphous solid dispersions of active pharmaceutical ingredients using polyvinyl alcohol. The application was filed on September 14, 2023, by inventors Lena Mueller, Laura Halstenberg, Thomas Kipping, and Nicole Di Gallo.
Patent Application: Solid Medicinal Forms with Stabilised Active Ingredient
The USPTO has published a new patent application (US20260083677A1) from Astellas Pharma Inc. The application describes solid medicinal forms containing active ingredients stabilized with specific drying agents, aiming for reduced moisture content. This is a new patent filing, not a regulatory rule or guidance.
Kit for Drug-Containing Nanoparticles and Composition for Drug Delivery
The USPTO has published a new patent application (US20260083682A1) by SAMYANG HOLDINGS CORPORATION for a kit and composition for constructing drug-containing nanoparticles for enhanced drug delivery. The application details a method utilizing cationic compounds and anionic polymers to improve cellular drug delivery efficiency.
Patent Application: Spray Dried Lipid Nanoparticle Formulations
The USPTO has published a patent application (US20260083681A1) detailing formulations for spray-dried lipid nanoparticle matrix particles. The application, filed on September 16, 2025, describes a composition including lipid nanoparticles, a buffer system, and a barrier matrix stabilizer. This publication is part of the patent application process and does not represent a final grant or regulatory requirement.
Mesoporous Nano-Magnesium Oxide for Drug Loading
The USPTO has published a patent application for a mesoporous nano-magnesium oxide material designed for drug loading. The application details the material's properties, including particle size and pore structure, and outlines a preparation method involving magnesium oxalate and CTAB.
Adagrasib Solid Pharmaceutical Compositions for Treating Cancer
The USPTO has published a new patent application (US20260083679A1) detailing solid pharmaceutical compositions containing adagrasib for treating cancer. The application, filed on December 3, 2025, includes methods for manufacturing these compositions and treating cancer.
Oral GLP-1 Compound Dosing Patent Application
The USPTO has published a patent application (US20260083678A1) related to oral dosing of GLP-1 compounds. The application was filed on December 3, 2025, by inventors Flemming S. Nielsen and Per Sauerberg, and relates to improved uses of GLP-1 peptides in oral therapy.
Sunscreen Compositions and Methods of Use
The USPTO has published a patent application from Mary Kay Inc. detailing new sunscreen compositions designed to protect skin from UV radiation. The application describes specific formulations involving film formers and organic UV filters, along with methods of making and using these compositions.
Anti-GPRC5D Antibody for Cancer Treatment
The USPTO has published a patent application (US20260085114A1) filed by Kyinno Biotechnology Co., Ltd. The application describes an anti-G protein-coupled receptor family class C group 5 member D (GPRC5D) antibody or fragment thereof for the treatment of tumors or cancers. It also details a bispecific antibody targeting GPRC5D and CD3.
Process for Isolating Osteopontin and Glycomacropeptide from Whey
The USPTO has published a new patent application (US20260085099A1) detailing a process for isolating osteopontin (OPN) and glycomacropeptide (GMP) from whey. The application, filed on September 15, 2023, describes a chromatography-based method for purification.
Patent Application: Method for Acute Respiratory Distress Syndrome Treatment
The USPTO has published a new patent application (US20260085098A1) from Revolo Biotherapeutics Limited for a method to treat acute respiratory distress syndrome. The application details a treatment method involving the administration of a specific peptide molecule during or in response to a relapse to induce remission.
DARPIN Compositions for Treating Shiga Toxin Diseases
The USPTO has published a patent application (US20260085097A1) detailing DARPIN-containing compositions for treating Shiga toxin diseases. The application highlights the thermostability and high microbial expression yield of DARPin as advantages over antibody therapeutics.
Patent Application: Detecting Pancreatic Cancer
The USPTO has published a patent application (US20260085360A1) detailing methods for detecting pancreatic cancer. The application describes a method involving measuring CA19-9 levels alongside other markers like OPN, MIA, and CEACAM-1 in a subject's sample.
Patent Application: Cancer Treatment Compositions and Methods
The USPTO has published a new patent application (US20260085120A1) for compositions and methods related to cancer treatment. The application describes binding agents, carrier proteins, and therapeutic agents, particularly for cancers expressing PD-LI or PD-L2, and lyophilized compositions.
Patent Application for Treating Cancer with Anti-CTLA4 Antibodies
The USPTO has published a new patent application (US20260085119A1) from ADAGENE PTE. LTD. for methods of treating cancers using anti-CTLA4 antibodies. The application details compositions and treatment methods, including combination therapies for cancers resistant to PD-1 or PD-L1 inhibitors.
Anti-CTLA-4 Antibody Conjugate Activated by Tumor Microenvironment
The USPTO has published a patent application (US20260085118A1) for a novel conjugate of an anti-CTLA-4 antibody activated by the tumor microenvironment. The application details a dual-activated conjugate designed to improve targeting efficacy, overcome drug resistance, and reduce toxicity.
Antibodies with chimeric constant domains reduce effector functions
The USPTO has published a patent application (US20260085117A1) detailing antibodies with chimeric constant domains designed to reduce effector functions. The application, filed on November 24, 2025, describes recombinant polypeptides and methods for their production.
Patent Application: Antibody Heavy Chain Regions Reduce Fc Gamma Receptor Binding
The USPTO has published a patent application (US20260085116A1) detailing antibody heavy chain constant regions modified to reduce binding to Fc gamma receptors. This modification, achieved through specific residue replacements or deletions in the hinge region, aims to decrease effector functions in antibodies and Fc fusion proteins.
CD3 Binding Antibodies Patent Application Inventors Listed
The USPTO has published a new patent application, US20260085115A1, related to CD3 binding antibodies. The application, filed on June 2, 2025, lists inventors Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, and Duy Pham.
Oil-in-water emulsions for topical administration with hyaluronan
The USPTO has published a patent application (US20260083673A1) for oil-in-water emulsions containing hyaluronan for topical administration. The application details formulations for treating various dermatological conditions, including inflammatory dermatoses, acne, alopecia, and fibrosing pathologies.
Patent Application for Stabilized Galectin-9 Protein Pharmaceutical Formulation
The USPTO has published a patent application (US20260083671A1) for a stabilized pharmaceutical formulation containing a recombinant stabilized galectin-9 protein. The application details a formulation designed for improved stability through the combination of a buffer and a stabilizer.
Adenovirus Formulation with Citrate Buffer and Salt
The USPTO has published a new patent application (US20260083670A1) for an adenovirus formulation. The formulation includes a recombinant adenovirus, citrate buffer, cyclodextrin compound, and salt, with a pH between 5.5 and 6.5, and is free of non-ionic detergent. The invention also covers a method for preserving adenoviruses using this formulation.
Aqueous Gel Composition for Administering Active Agents
The USPTO has published a new patent application, US20260083669A1, filed by Acousia Therapeutics GmbH. The application describes an aqueous gel composition useful for administering pharmaceutically active agents, particularly for transtympanic administration.
USPTO Patent for Orally Administered Corticosteroid Compositions
The USPTO has published a new patent application, US20260083668A1, for orally administered corticosteroid compositions. The patent, filed on November 28, 2025, by inventors Stephen Perrett, Fredric Jay Cohen, and Gopi M. Venkatesh, details pharmaceutical compositions and methods for treating gastrointestinal inflammation.
USPTO Patent Application for Disease Treatment Method
The USPTO has published patent application US20260083666A1 for a method of treating diseases and ameliorating pain by administering a composition to the ear canal. The application was filed on April 10, 2025, and published on March 26, 2026.
Sulforaphane Supplement in Gummy Form Patent Application
The USPTO has published a patent application (US20260083667A1) for a sulforaphane supplement in gummy form. The application, filed by Sensory Scout LLC, describes a composition including sulforaphane, glucoraphanin, and myrosinase immobilized within a gummy matrix. This represents a new patent filing for a novel supplement formulation.
USPTO Patent for Implantable Biodegradable Drug Delivery Devices
The USPTO has published a patent application (US20260083665A1) for implantable and biodegradable drug delivery devices. The invention aims to deliver active pharmaceutical ingredients directly to target tissue sites using layered biodegradable polymers.
Patent Application: Intrathecal T regulatory cells for Multiple Sclerosis Treatment
The USPTO has published a patent application (US20260083664A1) for a medicinal product involving intrathecal administration of T regulatory cells for treating multiple sclerosis. The application was filed on December 3, 2025, by inventors Piotr Trzonkowski and Kamil Chwojnicki.
Botanical Compositions and Methods of Production and Use
The USPTO has published a new patent application, US20260083663A1, detailing botanical compositions with plant extracts and their preparation methods. The application was filed on September 11, 2023, and is scheduled for publication on March 26, 2026. This represents a new disclosure of potential intellectual property in the pharmaceutical sector.
Skincare Therapeutic Balm Preparation Method Patent Application
The USPTO has published a patent application (US20260083662A1) for a skincare and therapeutic balm preparation method. The application, filed by Fine Washed LLC, details a method combining Ethiopian black seed oil with Illinois sourced beef tallow.
Cleansing composition with carnosine, magnesium, caffeine
The USPTO has published a new patent application (US20260083658A1) for a personal cleansing composition. The composition includes carnosine, magnesium salt, caffeine, and transdermal absorption enhancers, designed for use in products like shower gels and soaps.
Patent Application for Whitening Cosmetic Composition with Artemisinic Acid
The USPTO has published a patent application (US20260083657A1) for a whitening cosmetic composition containing artemisinic acid, nicotinamide, and/or glutathione. The application, filed by Yunnan Botanee Bio-Technology Group Co., Ltd., describes a formulation designed to inhibit melanin production and reduce skin irritation.
Patent Application for Hyaluronic Acid Production Stimulation
The USPTO has published a new patent application (US20260083656A1) filed by Alastin Skincare, Inc. The application details compositions and methods for stimulating intrinsic hyaluronic acid production to improve skin moisture and elasticity. This is a routine publication of a patent application.
Patent Application: Compositions with Sophorolipids and Lactic Acid
The USPTO has published a new patent application (US20260083655A1) filed by Evonik Operations GmbH. The application describes compositions containing sophorolipids and lactic acid for cleaning or skin moisturizing. This is a routine filing for a new patent application.
Patent Application for Genome Editing Compositions and Methods
The USPTO has published a new patent application (US20260083860A1) for genome editing compositions and methods. The application, filed on August 19, 2025, by inventors Oscar ALVAREZ, Ming-Yue LEE, and Blair B. MADISON, details methods and compositions for functional genetic modifications.
Patent Application: Tumor Targeting Methods and Reagents
The USPTO has published a patent application (US20260083867A1) detailing methods and reagents for tumor targeting in cancer treatment. The application, filed on November 21, 2025, describes a combination therapeutic approach using agents with different biodistributions to enhance efficacy and reduce toxicity.
USPTO Patent Application for PSMA Ligands
The USPTO has published a new patent application (US20260083865A1) filed by 3B Pharmaceuticals GMBH for prostate specific membrane antigen (PSMA) ligands. The application details a compound of Formula (I) and its use in treating cancer.
Patent Application for Contrast Agents in Diagnostic Imaging
The USPTO has published a patent application (US20260083864A1) for a new class of compounds intended for use as contrast agents in diagnostic imaging, including computed tomography (CT) and magnetic resonance imaging (MRI). The application details specific compound formulas, metal chelates, and preparation methods.
Patent Application: Treating Brain Diseases with rAAV Particles
The USPTO has published a new patent application (US20260083862A1) from the University of Iowa Research Foundation detailing methods for treating brain diseases using rAAV particles administered via the cisterna magna. The application was filed on May 19, 2025.
CRISPR Methods Targeting CD70 Expression for Engineered Cells
The USPTO has published a patent application (US20260083861A1) filed by Editas Medicine, Inc. The application describes CRISPR-related systems and methods for targeting the CD70 gene expression in engineered cells, particularly T cells, for potential therapeutic applications.
TEMIMAR trademark application published for opposition
The USPTO has published the trademark application for 'TEMIMAR' for opposition. The application covers natural herbal supplements, vitamin supplements, and other health-related food products. The publication date is March 25, 2026.
Vitaminloft Intent to Use Trademark Application
The USPTO has published details for an intent-to-use trademark application for the mark 'VITAMINLOFT'. The application covers a wide range of pharmaceutical and health-related products, including supplements, vitamins, topical preparations, and disinfectants.
VALISSE intent to use trademark application filed
The United States Patent and Trademark Office (USPTO) has received an intent-to-use trademark application for the mark 'VALISSE'. The application, filed on March 24, 2026, covers health food supplements, dietary supplements, herbal supplements, and vitamin and mineral supplements.
KARENZA Trademark Intent to Use Application
The USPTO has received an intent-to-use trademark application for the mark 'KARENZA' for use with dietary supplements. The application was filed on March 24, 2026, and is designated for Class 005.
PRÜF Intent to Use Trademark Application Filed
The USPTO has received an intent-to-use trademark application for the mark 'PRÜF' filed on March 25, 2026. The application, filed on September 24, 2025, pertains to dietary and nutritional supplements.
HIVANO Intent to Use Trademark Application
The USPTO has received an intent-to-use trademark application (TM99722503) for the mark 'HIVANO'. The application covers a wide range of goods including athletic apparel, footwear, and various supplements (probiotic, homeopathic, mineral, herbal, vitamin, calcium, food, dietary, nutritional, and natural herbal). It also includes services related to nutrition counseling and information provision.
POWERSTOVE Trademark Application Published for Opposition
The USPTO has published the trademark application for 'POWERSTOVE' for opposition. The application covers a range of products including personal sexual lubricants, dietary supplements, pet supplements, vitamins, and other health-related items. The publication date for opposition is March 25, 2026.
7 LIFE Trademark Application Published for Opposition
The USPTO has published the trademark application for '7 LIFE' for opposition. The application, filed on March 24, 2026, is for dietary supplements. The publication date is March 25, 2026, initiating a period for potential opposition.
CHIGGER OFF Intent to Use Trademark Application
The USPTO has received an Intent to Use trademark application for 'CHIGGER OFF' for topical dermatological preparations. The application was filed on March 24, 2026, with an effective date of March 25, 2026. This filing pertains to a new product intended to treat insect bites and stings.
FIBRIBION Trademark Publication
The USPTO has published the FIBRIBION trademark application for opposition. The application covers nutritional supplements, probiotic compositions, and dietary supplements. The publication date is March 25, 2026.
JUVONA intent to use trademark application filed
The USPTO has received an intent-to-use trademark application for the mark 'JUVONA' filed on March 25, 2026. The application covers goods including dietary supplements, nutritional supplements, and nutraceuticals for human consumption.
HEALTHYBLOOD Trademark Published for Opposition
The USPTO has published the HEALTHYBLOOD trademark application for opposition. The application covers various types of nutritional and dietary supplements. The publication date was March 25, 2026, with a filing date of March 24, 2026.
VERIXA trademark application published for opposition
The USPTO has published the trademark application for 'VERIXA' for opposition. The application covers insect repellents, insecticides, and rodenticides. The filing date was March 24, 2026, and the publication date is March 25, 2026.
BIOTHRIVE Trademark Application - Intent to Use
The USPTO has received an intent-to-use trademark application for the mark 'BIOTHRIVE' filed on March 24, 2026. The application covers health food supplements, dietary supplements, herbal supplements, and vitamin and mineral supplements.
ELTHYSIA Trademark Application - Intent to Use
The USPTO has recorded an intent-to-use trademark application for the mark 'ELTHYSIA'. The application covers a wide range of products including vitamins, dietary supplements, and pet supplements. The filing date for this application was March 24, 2026.
ASTANEURO Trademark Application Published for Opposition
The USPTO has published the trademark application for ASTANEURO, filed on March 24, 2026, for opposition. This notice indicates the application is now open for challenges from other parties before it can be registered.
NALIRFAL Trademark Application Published for Opposition
The USPTO has published the trademark application for NALIRFAL, which includes a variety of dietary and nutritional supplements. The application was published for opposition on March 25, 2026, with a filing date of March 24, 2026. This publication initiates a period during which other parties may oppose the trademark registration.
NOURISHA intent to use trademark application details
The USPTO has recorded an intent-to-use trademark application (TM99692572) for the mark 'NOURISHA'. The application covers a range of pharmaceutical and food-related products, including milk-based nutritional supplements and dietetic preparations. The filing date for this application was March 10, 2026.
KYNTO Trademark Published for Opposition
The USPTO has published the KYNTO trademark application for opposition, related to dietary supplements. The application was filed on March 24, 2026, and the publication date for opposition is March 25, 2026. This marks a step in the trademark registration process.
JOINT AND JOINT Trademark Published for Opposition
The USPTO has published the trademark application for 'JOINT AND JOINT' for health food supplements, initiating a 30-day opposition period. The application was filed on March 24, 2026, and published for opposition on March 25, 2026.
MAGEA4 Specific T Cell Receptors Patent Application
The USPTO has published a patent application (US20260085105A1) filed by Amgen Inc. for recombinant T-cell receptors designed to selectively recognize MAGE-A4-derived peptides. The application details screening for cross-reactivity and alloreactivity.
USPTO Patent Application for Fusion Polypeptides
The USPTO has published a new patent application (US20260085300A1) detailing systems and compositions for fusion polypeptides and their methods of use in regulating target genes. The application was filed on October 27, 2023, by inventors Thomas Blair Gainous, Xiao Yang, Giovanni Carosso, Lei S. Qi, and Daniel O. Hart, II.
Base Editing of Plant Cell Organelle DNA
The USPTO has published a patent application (US20260085323A1) detailing a method for base editing plant cell organelle DNA. The application, filed by the Institute for Basic Science, describes a composition and method for editing adenine to guanine and cytosine to thymine in plant cell organelle DNA.
Metabolic Selection via Serine Biosynthesis Pathway Patent Application
The USPTO has published a new patent application, US20260085327A1, related to metabolic selection via the serine biosynthesis pathway. The application details an isolated mammalian cell with reduced expression of Phosphoserine Phosphatase (PSPH) and its use in recombinant protein production.
Patent Application for Endoglin Antibodies Detecting Cancer Splice Variants
The USPTO has published a patent application (US20260086096A1) for endoglin antibodies designed to detect cancer splice variants. The application, filed by Nam Yong Lee, details methods and compositions for improved cancer diagnosis.
Karyocreate Patent Application US20260085330A1 Details CRISPR Technology
The USPTO has published patent application US20260085330A1 from Karyocreate detailing CRISPR technology for inducing aneuploidy. The application, filed on September 8, 2023, describes fusion proteins and guide RNAs that interfere with chromosome segregation.
Cell Culture Method Suppressing Foam Aggregates
The USPTO has published a new patent application (US20260085282A1) from FUJIFILM Corporation detailing a cell culture method. The method aims to suppress foam aggregate formation by adjusting poloxamer concentration or foam liquid viscosity during cell culture at high densities.
Anti-CD157 Antibodies, Fragments, Compositions, and Methods
The USPTO has published a patent application (US20260085128A1) detailing anti-CD157 antibodies, antigen-binding fragments, compositions, and methods for their use. The application was filed on July 18, 2023, and describes potential diagnostic reagents and kits.
Bispecific Antibody Targets TIM-3 and CD39 for Cancer
The USPTO has published a patent application (US20260085127A1) for a bispecific antibody designed to target both TIM-3 and CD39 antigens. This antibody aims to enhance immune activity against cancer cells and is intended for cancer treatment.
Methods for Separating Chelator from Mixture Using Chromatography
The USPTO has published a new patent application, US20260085108A1, detailing methods for separating a chelator from a mixture using chromatography. This application, filed on September 8, 2023, by inventors Jason Huang and Qiang Li, describes techniques useful in adjusting the concentration of chelators in protein compositions.
Ginkgo Bioworks Patent for Protein Production and Secretion Systems
The USPTO has published a new patent application (US20260085107A1) filed by Ginkgo Bioworks, Inc. The patent describes expression systems for enhanced production and secretion of proteins, including specific examples like bovine lactoferrin. This application is part of the ongoing patent process for novel biotechnological methods.
Chimeric Antigen Receptor System for Signalling
The USPTO has published a new patent application, US20260085106A1, detailing a chimeric antigen receptor (CAR) system. This system is designed to control signalling based on the presence or absence of a specific agent, potentially impacting the development of targeted therapies.
Polyproline Nanocage Compound and Manufacturing Method
The USPTO has published a patent application for a polyproline nanocage compound and its manufacturing method. The application details a compound comprising two cyclic peptide scaffolds connected by molecules, with each scaffold containing polyproline helix rods and turn-angle molecules. This is a routine publication of a new patent application.
Patent Application for Detecting Immune Cells Using Fusion Proteins
The USPTO has published a new patent application (US20260085104A1) detailing fusion proteins for detecting and isolating immune cells. The application, filed by Patrick Schlegel, describes specific fusion proteins involving a dysfunctional purinergic P2X7 receptor epitope and an antibody Fc region.
Long-acting insulin compound for treating diabetes
The USPTO has published a patent application (US20260085103A1) for a long-acting insulin compound designed for treating diabetes. The application details the compound's use in pharmaceutical compositions for conditions including type-I, type-II, and gestational diabetes.
Patent Application for Synthetic Promoters and Circuits in Cancer Cells
The USPTO has published a patent application (US20260085102A1) for nucleic acid molecules designed to specifically express sequences of interest in cancer cells. The application details synthetic promoters and circuits for use in cancer treatment.
Novel Platelet Derived Growth Factor Peptide Mimetic for Cardiac Repair
The USPTO has published a patent application (US20260085101A1) for a novel platelet-derived growth factor peptide mimetic designed for cardiac repair, particularly post-infarction. The application details specific compounds, their preparation, and methods of use.
US Patent Application for Antigen Production Methods
The USPTO has published a new patent application (US20260085100A1) from The Wistar Institute of Anatomy and Biology detailing methods for manufacturing individualized vaccines. The application focuses on nucleic acid molecules encoding neoantigens specific to tumor antigens for use in subject immunization.
Stabilized trimeric class I fusion proteins patent application
The USPTO has published a patent application (US20260085096A1) for stabilized trimeric class I fusion proteins. The application details specific mutations in the HR2 domain to enhance protein stability. This is a routine publication of a new patent application.
Patent Application for AAV Capsid Variants and Uses
The USPTO has published a new patent application (US20260085095A1) detailing adeno-associated virus (AAV) capsid variants and their uses. The application was filed on June 1, 2023, and is scheduled for publication on March 26, 2026. This represents a new disclosure in the field of gene therapy vectors.
Stapled Peptide and Use Thereof Patent Application
The USPTO has published a patent application (US20260085094A1) for a stapled peptide and its use, filed by inventors Zhixiang PAN, Haiying HE, Zhigan JIANG, and Shuhui CHEN. The application details a series of stapled peptides, specifically relating to polypeptides with sequences shown in formulas (I-1)-(I-5) and (II-6), and their pharmaceutically acceptable salts.
Melanocortin Receptor Ligands Patent Application
The USPTO has published a new patent application (US20260085092A1) for compounds acting as ligands for melanocortin receptors. The application details specific compounds and their potential use in treating mammals, filed by inventors Zeng Xin Dong and Jacques-Pierre Moreau.
Patent Application: Peptide Binds Trop2 for Cancer Treatment
The USPTO has published a patent application (US20260085091A1) from Kyungpook National University Industry-Academic Cooperation Foundation for a peptide that selectively binds to Trop 2. The peptide is intended for targeted therapeutic agents and anticancer drugs for resistant cancers such as breast, pancreatic, and cholangiocarcinoma.
Method for Reducing Host Cell Proteins in Affinity Chromatography
The USPTO has published a patent application from Genentech, Inc. detailing a method for purifying antibodies by reducing host cell proteins using a low conductivity aqueous solution in affinity chromatography. This application, filed on December 2, 2025, describes a specific purification technique for biopharmaceutical products.
Patent Application for Chromatographic Fractionation Method
The USPTO has published a new patent application (US20260085089A1) detailing a method and apparatus for continuous gradient elution chromatographic fractionation. The application, filed on September 12, 2023, describes a process for separating products of interest from impurities using chromatography matrices and elution solutions.
Method for preparing biologically active complexes using polypeptides and oleic acid
Method for preparing biologically active complexes using polypeptides and oleic acid
Patent Application for Apelin Receptor Binding Polypeptides and Methods
The USPTO has published a new patent application (US20260085125A1) for apelin receptor binding polypeptides and methods of treatment. The application was filed on November 25, 2025, and details antibodies and polypeptides that specifically bind to the apelin receptor (APJ).
Patent Application for Tenosynovial Giant Cell Tumor Treatment
The USPTO has published a patent application (US20260085124A1) detailing compositions and methods for treating tenosynovial giant cell tumor using intra-articular delivery of anti-CSF1R antibodies. The application, filed by Kirk William Johnson, focuses on sustained drug exposure within joints.
Patent Application: Anti-FGFR2 Antibodies with Chemotherapy for Cancer Treatment
The USPTO has published patent application US20260085123A1, filed by Five Prime Therapeutics, Inc. The application details the use of anti-FGFR2 antibodies in combination with mFOLFOX6 chemotherapy for treating certain cancers.
Patent Application: Antibodies Binding Human 4Ig-B7H3
The USPTO has published a new patent application (US20260085122A1) filed by BeOne Medicines I GmbH. The application relates to antibodies or antigen-binding fragments thereof that bind to human 4Ig-B7H3.
Patent Application: Multispecific Binding Constructs Against Checkpoint Molecules
The USPTO has published a new patent application (US20260085121A1) from Compass Therapeutics, LLC, detailing multispecific binding constructs against checkpoint molecules. The application focuses on compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression, specifically blocking interactions between PD-1 and its ligand.
All-in-one Agonistic Antibodies Patent Application
The USPTO has published a patent application (US20260085113A1) filed by Hoffmann-La Roche Inc. on October 2, 2025. The application describes antigen binding molecules comprising biparatopic target-binding domains and cytokine receptor-binding domains designed to selectively activate cytokine receptors.
Patent Application for Free LIGHT Detection and Treatment
The USPTO has published a patent application (US20260085112A1) from Avalo Therapeutics, Inc. for methods of detecting and treating conditions associated with elevated free LIGHT using anti-LIGHT antibodies. The application covers methods for diagnosing conditions like acute lung injury, ARDS, and Crohn's Disease.
Patent Application for SLIT2 Related Compositions and Methods
The USPTO has published a new patent application (US20260085111A1) filed by EVEREST MEDICINES (SINGAPORE) PTE. LTD. The application relates to antibodies that bind to SLIT2 and related substitution mutants, including their manufacture and use.
Patent Application: Production Method for Product to Prevent Membrane Clogging
The USPTO has published a patent application from FUJIFILM Corporation detailing a production method for a product that aims to prevent membrane clogging during cell culture. The method involves specific mathematical expressions related to poloxamer concentration, product concentration, and hydrophobicity index to optimize the cell culture process.
CD163 Binding Protein Patent Application
The USPTO has published a patent application (US20260085129A1) filed by ECO ANIMAL HEALTH LTD. on October 11, 2023. The application relates to an antibody that binds to porcine CD163, specifically its membrane-bound form.
Takeda's Monoclonal Antibody Inhibitor of Factor XIIa Patent Application
The USPTO has published a patent application from Takeda Pharmaceutical Company Limited for a monoclonal antibody inhibitor of Factor XIIa. The application, filed on August 12, 2025, describes methods for treating diseases associated with Factor XII, including hereditary angioedema and ocular diseases.
Patent Application: Bispecific Antibodies and Uses Thereof
The USPTO has published a new patent application (US20260085131A1) for bispecific antibodies and their uses. The application, filed on August 20, 2025, describes antibodies that bind to two different antigens with varying affinities.
Heterodimeric Human IgG1 Polypeptides with Isoelectric Point Modifications
The USPTO has published a new patent application, US20260085132A1, titled 'Heterodimeric Human IgG1 Polypeptides with Isoelectric Point Modifications'. The application details methods for purifying desired heterodimer immunoglobulin variants from contaminating homodimer variants by modifying isoelectric points.
Patent Application: Filtration Condition Evaluation and Cell Product Production
The USPTO has published a new patent application (US20260085109A1) from Asahi Kasei Life Science Corporation detailing a method for evaluating filtration conditions and producing cell products. The application was filed on November 14, 2023, and published with a projected application date of March 26, 2026.
Patent Application for Agonistic TNF Receptor Binding Agents
The USPTO has published a new patent application, US20260085126A1, for agonistic TNF receptor binding agents. The application, filed on August 27, 2025, by inventors including Ugur Sahin, details binding agents for TNF superfamily receptors and their potential medical uses.
Resoundant Acoustic Transducer for MRI - Safety Action
The French National Agency for Medicines and Health Products Safety (ANSM) has registered a safety action concerning the Resoundant acoustic transducer for MRI, identified under number R2606244. Healthcare facilities and medical imaging centers using this device have been notified.
Product Recall: Klassiker Crutches and Rubber Tips
The ANSM has been informed of a product recall for Klassiker crutches and rubber tips, initiated by Ossenberg GmbH. This safety action, registered under number R2603198, affects pharmacies, community care facilities, large and medium-sized stores, and home healthcare providers. Affected users have been notified directly by the manufacturer.
ANSM Security Alert for Orbis Medication Prescription Aid Software
The ANSM has issued a security alert (R2608925) regarding the Orbis Medication prescription aid software (version 3.x) from DH Healthcare GMBH. Affected healthcare providers have been notified directly by the company.
ANSM Safety Alert: Atellica CH Urine Albumin Reagent
The French National Agency for Medicines and Health Products Safety (ANSM) has issued a safety alert regarding the Atellica CH Urine Albumin reagent from Siemens Healthcare Diagnostics Inc. The alert, registered under number R2602998, informs medical biology laboratories of a safety action implemented by the manufacturer.
Safety Recall: Omnipaque and Visipaque Injectable Solutions
The French National Agency for Medicines and Health Products Safety (ANSM) has issued a safety recall for specific lots of Omnipaque and Visipaque injectable solutions manufactured by GE Healthcare SAS. The recall is due to the potential presence of particles adhering to the inner wall of the vials, posing a risk to patients if injected.
Bifunctional degraders with electrophilic PROTACs
The USPTO has published a patent application (US20260083722A1) detailing bifunctional degraders comprising electrophilic PROTACs that engage DCAF1. The application was filed on May 19, 2023, and published with a projected application date of March 26, 2026.
Phytogenic Composition for Animal Skeletal Muscle Growth
The USPTO has published a patent application (US20260083805A1) detailing a phytogenic composition comprising Glycyrrhiza uralensis extract for promoting skeletal muscle growth in animals. This application outlines its use as a feed additive for agricultural applications.
Patent Application for Reducing Blood Glucose with Plants
The USPTO has published a new patent application (US20260083803A1) detailing methods and compositions for reducing fasting blood glucose in mammals using plants like Dichrostachys glomerata or Cissus quadrangularis. The application was filed on September 26, 2024, and is expected to be published on March 26, 2026.
Patent Application for Reducing Visceral Fat Using Plants
The USPTO has published a new patent application (US20260083801A1) detailing methods and compositions for reducing visceral fat in mammals using plants like Dichrostachys glomerata or Cissus quadrangularis. The application was filed on September 26, 2024, and is expected to be published on March 26, 2026.
Patent application for Dichrostachys glomerata health and wellness benefits
Patent application for Dichrostachys glomerata health and wellness benefits
Patent Application: Reducing DPP-4 Activity Using Plants
The USPTO has published a new patent application (US20260083804A1) detailing methods and compositions for reducing DPP-4 activity using plants like Dichrostachys glomerata or Cissus quadrangularis. The application, filed on September 26, 2024, aims to provide health benefits such as increased GLP-1 levels and reduced visceral fat.
Patent Application: Methods for Reducing Blood Lipids Using Plants and Spices
The USPTO has published a new patent application (US20260083802A1) detailing methods and compositions for reducing blood lipids using plants and spices, specifically Dichrostachys glomerata or Cissus quadrangularis. The application was filed on September 26, 2024.
Patent Application for Reducing Food Intake Using Plants
The USPTO has published a new patent application (US20260083800A1) detailing methods and compositions using Dichrostachys glomerata or Cissus quadrangularis to reduce food intake or appetite in mammals. The application was filed on September 26, 2024, by inventors Shil Kothari and Julius Enyoug Oben.
Patent Application for Pyrazolylcarboxamide Compounds for Therapy
The USPTO has published a patent application (US20260085073A1) for pyrazolylcarboxamide compounds and their use in therapy. The application details compounds that inhibit MALT1 and their potential treatment for proliferative, inflammatory, or autoimmune disorders.
USPTO Patent Application for Cancer Prodrugs
The USPTO has published a patent application (US20260085069A1) for novel prodrug compounds designed to treat cancer and other diseases by inhibiting Casein Kinase 2 alpha (CK2α). The application details specific chemical structures and their potential pharmaceutical uses.
Pritelivir Crystalline Form Patent Application
The USPTO has published a patent application (US20260085068A1) filed by Assembly Biosciences, Inc. on August 28, 2023. The application describes a novel crystalline form of the antiviral drug pritelivir, intended for the treatment of herpes virus.
Cyclic Sulfonamide RNR Inhibitors for Cancer Treatment
The USPTO has published a new patent application, US20260085067A1, detailing cyclic sulfonamide RNR inhibitors for cancer treatment. The application was filed on September 12, 2023, by inventors Anthony B. Pinkerton, Jacques Mauger, and Yen Pham Hong Truong.
LRRK2 Degrading Compounds for Parkinson's Disease Treatment
The USPTO has published a new patent application (US20260085066A1) detailing bifunctional compounds designed to degrade LRRK2, a protein implicated in Parkinson's Disease. The application covers pharmaceutical compositions and methods for treating LRRK2-associated disorders.
Patent for SGLT Inhibitor Synthesis Intermediate
The USPTO has published a patent application for a crystalline form of an intermediate useful in the synthesis of SGLT inhibitors. The application details a method to improve purification efficiency and minimize related substances in the final product, potentially increasing yield.
Patent Application: Benzofuranyl/Benzoxazolyl Compounds for Cancer Treatment
The USPTO has published a patent application (US20260085064A1) for substituted benzofuranyl and benzoxazolyl compounds, including their synthesis and use in treating cancer. The application was filed on May 2, 2025, by inventors from institutions including the University of Texas MD Anderson Cancer Center.
Patent Application: Benzamide Compounds for SARS-CoV-2 PLpro Inhibition
The USPTO has published a new patent application (US20260085063A1) detailing benzamide compounds and methods for inhibiting SARS-CoV-2 PLpro. The application was filed on August 19, 2025, by inventors Jun Wang, Bin Tan, and Prakash Daulat Jadhav.
Novel compounds as CK2 inhibitors for disease treatment
The USPTO has published a patent application (US20260085062A1) for novel compounds identified as CK2 inhibitors. These compounds are intended for the treatment and prevention of various diseases, including cancer, viral infections, and neurodegenerative disorders. The application details specific chemical structures and their potential pharmaceutical uses.
Patent Application: Phthalazine Derivatives as Pyruvate Kinase Modulators
The USPTO has published a new patent application (US20260085061A1) for phthalazine derivatives as pyruvate kinase modulators, assigned to Sitryx Therapeutics Limited. The application was filed on September 25, 2025.
Patent Application: Therapeutic Compounds - Orexin-1 Receptor Antagonists
The USPTO has published a new patent application (US20260085060A1) for therapeutic compounds that act as orexin-1 receptor antagonists. The application, filed on September 25, 2025, details compounds with structural formula (I), their preparation, and pharmaceutical uses.
System for updating medical facility uses AI
The USPTO has published a patent application for a system that uses AI to determine whether to update a medical facility. The system retrieves information from the facility, applies an AI model, and initiates maintenance or upgrades based on the determination. The application was filed on September 4, 2023.
Patent Application US20260085058A1 for SOS1 Degraders Treating Cancers
The USPTO has published patent application US20260085058A1, which relates to compounds that degrade son of sevenless homolog 1 (SOS1) and their use in treating cancers, particularly KRAS-mutant cancers. The application was filed on August 11, 2023.
OX1 Receptor Antagonists Patent Application
The USPTO has published a new patent application (US20260085056A1) filed on May 9, 2025, by NXERA PHARMA UK LIMITED. The application relates to novel compounds for treating neurological or psychiatric disorders associated with orexin receptors.
Patent Application for Recyclable Polymer Material and Monomer
The USPTO has published a patent application (US20260085055A1) for a novel monomer and a chemically recyclable polymer material comprising the same. The application, filed by the Korea Institute of Science and Technology, describes a monomer formed by bonding a pentagonal cyclic olefin molecule with a photosensitive molecule to enable chemical recycling.
Hispidin Derivative Synthesis Method and Use
The USPTO has published a patent application (US20260085054A1) detailing a new method for synthesizing Hispidin derivatives and their use in preparing lipid-lowering drugs. The application describes a process using readily available starting materials with potential for large-scale industrial application.
Patent Application for Benzofuran Derivatives as SIK Inhibitors
The USPTO has published a patent application (US20260085053A1) from BEONE MEDICINES I GMBH for benzofuran derivatives that act as SIK inhibitors. These compounds are intended for the treatment of various inflammatory diseases.
Patent Application for Furan Derivative Oxidation Process
The USPTO has published a patent application (US20260085052A1) detailing a new process for producing 2,5-furandicarboxylic acid. The application, filed by David Lee Sikkenga and Jan Hendrik Blank, describes a specific oxidation method involving furan derivatives, oxidants, solvents, and catalysts.
Patent Application for 2-Chloro-4-Fluoro-5-Nitrobenzoic Acid Preparation
The USPTO has published a patent application (US20260085051A1) detailing a novel nitration process for preparing 2-chloro-4-fluoro-5-nitrobenzoic acid. The assignee is ADAMA AGAN LTD. This compound is used in the synthesis of the herbicide saflufenacil.
Triple Kinase Inhibitors for Cancer Treatment
The USPTO has published a patent application (US20260085050A1) for triple kinase inhibitor compounds designed for cancer treatment. The application details compounds that inhibit EGFR, ALK, and MET simultaneously, along with methods for treating cancer using these inhibitors.
Ergothioneine Crystal Form Patent Application
The USPTO has published a patent application (US20260085049A1) for a novel crystal form of ergothioneine and its preparation method. The application details a method for producing high-purity ergothioneine with low moisture content, intended for use in dietary supplements, foods, and cosmetics.
ACSS2 Inhibitors for Cancer, Alcoholism, Viral Infections
The USPTO has published a patent application (US20260085048A1) detailing novel ACSS2 inhibitors and their potential uses in treating cancer, alcoholism, and viral infections. The application was filed on September 8, 2025.
Triphenylazole Compound Patent Application for Synucleinopathy Treatment
The USPTO has published a patent application (US20260085047A1) filed by Shiratori Pharmaceutical Co., Ltd. for a triphenylazole compound intended for the treatment or prevention of synucleinopathy. The application details the compound's structure and its potential use in pharmaceutical compositions.
Patent Application: Dual Function Compounds for Cancer Treatment
The USPTO has published patent application US20260085046A1, filed on August 7, 2025, for dual function compounds intended for cancer treatment. The application discloses compounds of Formula (I) and their use in treating cancer.
Patent Application for Nitrogen-Containing Heterocyclic Derivative Inhibitor
The USPTO has published a patent application (US20260085045A1) for a nitrogen-containing heterocyclic derivative inhibitor. The application details a compound, its preparation method, and its use in treating diseases such as cardiovascular and cerebrovascular conditions.
Salts and Solid Forms of 4-hydroxy-N,N-diisopropyltryptamine
The USPTO has published a patent application detailing new salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DIPT), including hemi-glutarate and hemi-succinate forms. These forms are disclosed for their potential use in treating neurological and psychiatric disorders.
Patent Application for 4-Amino-5-Methyl Pyridin-2-One Production Process
The USPTO has published a patent application (US20260085044A1) detailing an improved process for producing 4-amino-5-methyl-(1H)-pyridin-2-one and its derivatives. The application, filed by MinAscent Technologies GmbH, describes a method using ammonium salts under pressure without gaseous ammonia, aiming for high yield and purity while reducing container corrosion.
Patent Application: Initiator Mixture and Polymer Composition
The USPTO has published a new patent application (US20260085043A1) detailing an initiator mixture, a composition including it, and a polymer formed from the composition. The application was filed on September 18, 2025, by inventors from South Korea.
Method for Preparing Indigo or Substituted Derivative
The USPTO has published a patent application (US20260085042A1) detailing a method for synthesizing indigo or substituted derivatives. The application, filed on June 16, 2023, describes a process involving anthranilic acid and glyoxylic acid under hydrogenation with a metal catalyst.
Patent Application for Chromophores with New Ring-Locked Donors
The USPTO has published a new patent application (US20260085189A1) filed by Lightwave Logic, Inc. The application describes novel nonlinear optical (NLO) chromophores with ring-locked donors designed to increase r33 and stability. The filing date was September 23, 2025.
Patent Application for Psilocin Derivatives for Treating Disorders
The USPTO has published a patent application (US20260085040A1) for psilocin derivatives, including carbohydrate and amino acid conjugates. These compounds are intended for the treatment of various neuropsychiatric, neurodegenerative, neuroinflammatory, and pain disorders.
Patent Application for GYS1 Inhibitors
The USPTO has published a patent application (US20260085034A1) for N-(BENZHYDRYL)CYCLOALKYLCARBOXAMIDE derivatives as inhibitors of Glycogen Synthase 1 (GYS1). The application details compounds and methods for preparing them, as well as methods for inhibiting GYS1 and treating GYS1-mediated diseases.
Patent Application for Artemisinic Acid Derivative Preparation
The USPTO has published a patent application (US20260085030A1) for an artemisinic acid derivative and its preparation method. The application, filed by Yunnan Botanee Bio-Technology Group Co., Ltd., aims to improve the water solubility of artemisinic acid and dihydroartemisinic acid while retaining their whitening, anti-inflammatory, and anti-tumor properties.
Chromophores with New Bridges that Increase Refractive Index
The USPTO has published a patent application (US20260085236A1) for Lightwave Logic, Inc., detailing new nonlinear optical (NLO) chromophores designed to increase refractive index. These chromophores offer improved electro-optic effects, modulation speed, photostability, and thermal stability, making them suitable for low-power, small-footprint electro-optic devices.
KDM1A Inhibitors for Disease Treatment Patent Application
The USPTO has published a new patent application (US20260085082A1) from Imago Biosciences, Inc. The application discloses new compounds and compositions for pharmaceutical use, specifically for inhibiting KDM1A and increasing gamma globin gene expression to treat diseases like acute myelogenous leukemia.
Patent Application: Janus Kinase Inhibitors by Chiesi Farmaceutici
The USPTO has published a patent application (US20260085077A1) filed by Chiesi Farmaceutici S.P.A. The application describes compounds of general formula (I) that inhibit Janus Kinase (JAK) family kinases. These compounds are intended for therapeutic use in treating inflammatory diseases.
Patent Application for Crystal Form of Aromatic Heterocyclic Compound
The USPTO has published a patent application (US20260085076A1) detailing a new crystal form (I and III) of an aromatic heterocyclic compound. The application also describes a production method and its use in treating diseases related to abnormal JAK-STAT signaling pathways.
Patent Application: Cancer Treatment Compositions and Methods
The USPTO has published a patent application (US20260085074A1) detailing compositions and methods for treating cancer by modulating K-Ras, a frequently mutated oncogene. The application was filed on June 17, 2025, by inventors Jonathan Ostrem, Ulf Peters, and Kevan M. Shokat.
Method for Preparing Intermediate of Adrenergic Receptor Agonist
The USPTO has published a patent application detailing a new method for preparing an intermediate of an adrenergic receptor agonist. The method claims to offer improved yield, reduced cost, and milder reaction conditions, making it more favorable for commercial production. The application was filed on December 4, 2025.
Substituted Indazoles for Treating Animal Allergic Inflammatory Diseases
The USPTO has published a patent application detailing the use of substituted indazoles for the treatment and prevention of allergic and inflammatory diseases in animals. The application, filed on October 9, 2025, outlines specific compounds and their potential applications in veterinary medicine.
US Patent Application: Non-Aqueous Electrolyte, Battery, Device
The USPTO has published a new patent application (US20260088357A1) for a non-aqueous electrolyte, secondary battery, and electric device. The application, filed by CONTEMPORARY AMPEREX TECHNOLOGY CO., LIMITED, details specific chemical compositions for electrolytes, including cyclic sulfate compounds and organic base additives. This publication represents a new disclosure in the field of battery technology.
Photoresist Molecular Group Structure, Synthesis, and Use Method
The USPTO has published a new patent application (US20260086460A1) for a bifunctional molecular group structure for photoresists, including a linker, PAG molecule, and PDQ molecule. The application also details synthesis and use methods for this structure, assigned to Shanghai Huali Integrated Circuit Corporation.
Psilocin Crystalline Forms Patent Application
The USPTO has published a patent application (US20260085039A1) detailing crystalline forms of psilocin, including salts and cocrystals. The application, filed by Jim Gilligan and Peter Guzzo, describes these forms as having improved physical properties like aqueous solubility and stability, suitable for various administration routes.
Novel Nootropic Prodrugs of Phenethylamine
The USPTO has published a patent application (US20260085036A1) for novel nootropic prodrugs of phenethylamine, assigned to MiHKAL GmbH. The application describes compounds designed to improve phenethylamine uptake and reduce side effects, potentially for treating conditions like depression and PTSD.
New Polymers and Methods Patent Application
The USPTO has published a new patent application, US20260085336A1, detailing processes for forming pyridinedicarboxylic acid derivatives and copolymers. The application, filed on September 25, 2025, outlines biocatalytic methods and potential uses for these new materials.
Patent Application for Novel Compound Treating Neurodegeneration and Cardiovascular Diseases
The USPTO has published a patent application (US20260085083A1) for a novel compound and pharmaceutical composition developed by SHANDONG RUZHI BIOMEDICINE TECHNOLOGY CO., LTD. The compound is intended for preventing or treating neurodegenerative diseases and cardiovascular/cerebrovascular diseases.
Protein Degraders Patent Application
The USPTO has published a new patent application, US20260085075A1, related to protein degraders and their uses. The application was filed on August 19, 2025, by inventors Nello Mainolfi, Nan Ji, Yi Zhang, and Matthew M. Weiss.
Patent Application for Novel Crystalline Form of Amine Compound
The USPTO has published a patent application (US20260085071A1) for novel crystalline forms of an amine compound, 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N-methylazetidin-3-amine. The application also discloses pharmaceutical compositions and the use of these forms for treating diseases such as atopic dermatitis and urticaria.
Patent Application for Cancer Treatment Compounds
The USPTO has published a new patent application (US20260085070A1) for heterocyclic CBL-B inhibitors intended for the treatment of cancer. The application was filed on April 7, 2025, by inventors Yingzhi BI, Kenneth G. CARSON, and Geraldine Cirillo HARRIMAN.
Organic Compound and Light-Emitting Device Patent Application
The USPTO has published a patent application (US20260090268A1) for an organic compound and a light-emitting device incorporating it. The application details specific chemical structures and their application in electronic apparatus. The filing date was September 8, 2025.
Organic electronic element and compound for improved hole transport
The USPTO has published a new patent application, US20260090270A1, filed by TOSOH CORPORATION. The application describes an organic electronic element and a compound designed to improve hole transport ability, potentially enhancing performance in electronic devices.
Mitsubishi Gas Chemical Organic Thin Film Patent Application
The USPTO has published a new patent application from Mitsubishi Gas Chemical Company, Inc. for a compound and organic thin film technology. The application, filed on December 14, 2023, details a specific molecular structure intended for use in photoelectric conversion elements and imaging devices.
Patent Application: Organic Light Emitting Device Compound
The USPTO has published a new patent application, US20260090199A1, detailing a novel organic compound for use in organic light-emitting devices. The application describes a compound that may offer improved driving voltage, efficiency, and service life compared to existing technologies.
Patent for Heterocyclic Compound Organic Light Emitting Device
The USPTO has published a patent application for a heterocyclic compound intended for use in organic light-emitting devices. The application, filed by Eui-Jeong Choi and others, describes a compound that may improve device efficiency and lifespan.
Patent Application for NLO Chromophores with New Acceptors
The USPTO has published a patent application (US20260085190A1) filed by Lightwave Logic, Inc. The application describes nonlinear optical (NLO) chromophores designed to increase refractive index, offering advantages in speed, photostability, and thermal stability for electro-optic devices.
WHO Report: 60+ Countries Include Refugees in Health Policies
The World Health Organization (WHO) released a report indicating that over 60 countries now include refugees and migrants in their national health policies. The report, based on data from 93 Member States, establishes a baseline for inclusive health systems but highlights remaining gaps in data collection, emergency preparedness, and culturally responsive care.
WHO Accredited by Green Climate Fund for Climate and Health
The World Health Organization (WHO) has been accredited by the Green Climate Fund (GCF), enabling access to new funding for climate and health initiatives. This accreditation will support projects aimed at protecting communities from the health impacts of climate change, particularly in low- and middle-income countries.
Dupilumab for Uncontrolled COPD with Raised Eosinophils
NICE has issued technology appraisal guidance TA1142 recommending dupilumab (Dupixent) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) and raised blood eosinophils. The guidance provides evidence-based recommendations for healthcare professionals.
Health Product InfoWatch: March 2026
Health Canada's March 2026 Health Product InfoWatch details recalls and safety updates for various medications, including Bicillin L-A, Bortezomib, Cefazolin, MAR-Amlodipine, and Seasonique/Seasonale. It also announces new market authorizations with conditions for Voxzogo and product monograph updates for Stivarga.
TGA Opens Consultation on Sunscreen Regulation Improvements
The Therapeutic Goods Administration (TGA) has opened an 8-week public consultation on proposed improvements to sunscreen regulation in Australia. The consultation seeks feedback on options to enhance SPF testing reliability, adopt new technologies, strengthen laboratory oversight, and improve labelling and quality assurance.
TGA Issues Infringement Notices for Unlawful Importation of Therapeutic Goods
The TGA has issued infringement notices totalling $23,760 to three health practitioners for allegedly importing unapproved therapeutic goods unlawfully. These goods, including unregistered botulinum toxin and hyaluronic acid, have not been assessed by the TGA and may pose health risks.
HHS and CMS Announce Healthcare Advisory Committee Members
HHS and CMS have announced the members of the new Healthcare Advisory Committee, a federal advisory body composed of healthcare leaders. The committee will provide non-binding recommendations to improve and modernize U.S. healthcare financing and delivery across Medicare, Medicaid, and other programs.
OIG Report: Part B Drug Payments Included Noncovered Self-Administered Versions, Increasing Costs
An HHS OIG report found that Medicare Part B payment amounts for the drug Omvoh included noncovered self-administered versions in 2024, increasing costs. Excluding these versions would have saved Part B and its enrollees an estimated $1,742 per vial in the fourth quarter of 2024. The report also noted that CMS's prior removal of noncovered self-administered versions for five other drugs saved $1.3 billion from 2023 through 2024.
OSHA Seeks Comments on Logging Operations Paperwork Extension
OSHA is requesting public comments on extending the Office of Management and Budget's approval for information collection requirements under the Standard on Logging Operations. This action is part of OSHA's ongoing effort to reduce employer burden and ensure information collection is necessary and efficient.
OSHA Intertek Testing Services Application Withdrawn
The Occupational Safety and Health Administration (OSHA) has withdrawn a document related to an Intertek Testing Services application. The document was identified as a duplicate that was inadvertently added to the docket.
Collagenase Compositions for Orthodontic Procedures Patent Application
The USPTO has published a patent application detailing compositions comprising collagenase and their uses in orthodontic procedures. The application, filed by inventors from Israel, describes potential uses for recombinant collagenase and modified forms thereof in dental treatments.
USPTO Patent Application for Tavapadon in Parkinson's Disease Treatment
The USPTO has published a patent application (US20260083740A1) detailing methods for treating Parkinson's Disease using escalating doses of tavapadon. The application was filed on September 23, 2025, by inventor Sridhar Duvvuri.
USPTO Patent Application for Photoprotective System
The USPTO has published a patent application (US20260083654A1) for a photoprotective system consisting of four specific sunscreens, assigned to PIERRE FABRE DERMO-COSMETIQUE. The application details a cosmetic or pharmaceutical composition with a photoprotective system representing 4% to 20% by weight.
USPTO Patent Application: Tooth Whitening Preparation System
The USPTO has published a patent application (US20260083653A1) for a tooth whitening preparation system and method filed by Cobea AG. The application describes a component system including an active ingredient component and an activation component designed to adjust the pH for a physiologically acceptable tooth whitening preparation.
USPTO Patent Application for Renewable Ester Emollient
The USPTO has published a patent application (US20260083652A1) for a renewable ester emollient for enhanced cutaneous permeation, assigned to Oxiteno S.A. Indústria e Comércio. The application details a personal care formulation and a method for moisturizing skin or hair using this emollient.
USPTO Patent Application for Skin Care Formulations
The USPTO has published a patent application (US20260083651A1) for skin care formulations. The application details a method of treating skin and a topical composition including various extracts and active ingredients. The filing date for this application was December 4, 2025.
USPTO Patent Application: Oral Care Compositions
The USPTO has published a new patent application from Colgate-Palmolive Company for oral care compositions containing amino acids and flavor components. The application details methods of making and using these stabilized compositions, aiming to combine traditionally incompatible ingredients.
USPTO Patent Application: Oral Care Composition with Mint Oil and Tin
The USPTO has published a new patent application (US20260083649A1) for an oral care composition. The invention involves a blend of mint oil, tin, and flavor extract designed to prevent the formation of methyl mercaptan, a compound that can cause unpleasant odors.
USPTO Patent Application: Deodorant Compositions
The USPTO has published a patent application (US20260083648A1) for deodorant compositions described by Dr. Squatch, LLC. The application details specific ingredient percentages for stick deodorants, emphasizing a high percentage of natural or naturally-derived ingredients.
USPTO Patent Application: Topical Delivery Systems
The USPTO has published a new patent application (US20260083647A1) detailing topical delivery systems and multi-phase formulations. The application describes sustained-release barrier formulations designed for skin application, potentially offering time-dependent effects like hair follicle softening and delayed active ingredient delivery.
USPTO Patent Application: Method for Forming Drops Dispersion
The USPTO has published a patent application detailing a method for forming a dispersion with fatty and aqueous phases, including specific steps for creating and conveying fatty phase drops. This application, filed by inventors Duncan Gilbert and Mathieu Goutayer, outlines a novel approach to dispersion formation for potential use in various product formulations.
USPTO Patent Application: RNA Complexes for Cancer Metastasis Treatment
The USPTO has published a new patent application detailing RNA complexes and nanostructures for cancer metastasis treatment. The application describes a one-step CMC production method for RNA therapeutic complexes containing nucleoside analogues, which self-assemble during RNA synthesis.
USPTO Patent Application: Inflammasome Inhibition for Neuroprotection
The USPTO has published a new patent application detailing methods for treating retinal detachment using inflammasome inhibition. The application, filed by Jayakrishna Ambati, Peirong Huang, and Kameshwari Ambati, focuses on improving visual outcomes for patients with rhegmatogenous retinal detachment.
USPTO Patent Application: Solid Dosage Form of Antiviral Nucleoside
The USPTO has published a new patent application from Merck Sharp & Dohme LLC for an oral dosage form of a small molecule antiviral nucleoside. The application details specific formulation components and pellet size requirements for the antiviral drug.
USPTO Patent Application: Neurodegenerative Disorder Treatment
The USPTO has published a new patent application (US20260083766A1) detailing methods for treating neurodegenerative disorders by modulating RNA editing. The application was filed on May 16, 2025, by inventors Nandkishore Raghav Belur and Joseph Robert Mazzulli.
USPTO Patent Application: Sialic Acid Compositions for Coronavirus Infections
The USPTO has published a patent application (US20260083762A1) detailing compositions comprising sialic acid for inhibiting or treating coronavirus infections, specifically those caused by SARS-CoV-2. The application was filed on August 18, 2025, by inventor Jan Remmereit.
USPTO Patent Application for NAD+ Concentration Support Compositions
The USPTO has published a patent application (US20260083765A1) for compositions and methods designed to support, optimize, and/or improve NAD+ concentrations in humans. The application details specific combinations of ingredients, including nicotinamide riboside, vitamins, and minerals.
USPTO Patent Application: Neuronal Migration Promoter for Brain Disease Treatment
The USPTO has published a patent application (US20260083761A1) from Public University Corporation Nagoya City University for a pharmaceutical composition and method to promote neuronal migration for treating brain diseases. The application details the use of a neuraminidase inhibitor.
USPTO Patent Application: Beta-1,3'-galactosyllactose for Gut Barrier Function Diseases
The USPTO has published a patent application (US20260083764A1) from N.V. Nutricia detailing the use of beta-1,3'-galactosyllactose for treating gut barrier function diseases, particularly in infants and young children. The application was filed on November 24, 2025.
USPTO Patent Application for Fiber-Based Prebiotic Dietary Supplements
The USPTO has published a patent application (US20260083763A1) for liquid compositions containing fiber as a prebiotic dietary supplement. The application details formulations designed to maintain or improve gut microbiome health.
USPTO Patent Application: Stable Liquid Bortezomib Formulations
The USPTO has published a patent application (US20260083760A1) for stable liquid bortezomib formulations filed by Riconpharma LLC. The application describes liquid compositions with specific impurity limits for intravenous or subcutaneous use.
USPTO Patent Application: Psychedelics Combined with NMDA Receptor Agonists
The USPTO has published a patent application (US20260083759A1) detailing combinations of psychedelic drugs with NMDA receptor agonists for treating neuropsychiatric and neurologic disorders. The application was filed on August 29, 2023, and is scheduled for publication on March 26, 2026.
USPTO Patent Application for Self-Emulsifying Drug Delivery Systems
The USPTO has published a patent application from Fertin Pharma A/S for a dosage form utilizing self-emulsifying drug delivery systems (SEDDS) for cannabinoids. The application details specific formulations including surfactants with PEG moieties and isolated or synthetic cannabinoids.
USPTO Patent Application for Tyk2 Inhibitor Dosage Forms
The USPTO has published a patent application (US20260083734A1) for novel dosage forms of Tyk2 inhibitors, specifically BMS-986165, intended for treating autoimmune and inflammatory diseases. The application details stable and bioavailable formulations, including spray-dried dispersions in a polymer matrix.
USPTO Patent Application: Cannabinoid Delivery Capsules
The USPTO has published a new patent application (US20260083756A1) from Fertin Pharma A/S for capsules designed for peroral cannabinoid delivery. The application details formulations using self-emulsifying drug delivery systems (SEDDS) with specific surfactant and cannabinoid content.
USPTO Patent Application: TYK2 Inhibitor Dosage Forms
The USPTO has published a patent application (US20260083733A1) for novel dosage forms of a TYK2 inhibitor, BMS-986165, intended for treating autoimmune diseases. The application details stable and bioavailable formulations, including spray-dried dispersions in a solid polymer matrix.
Testosterone Composition for Oral Delivery Treats Hypogonadism
The USPTO has published a patent application (US20260083755A1) assigned to NEUROCRINE UK LIMITED for a testosterone-containing pharmaceutical composition adapted for oral delivery. The application details treatment regimens and methods for hormone-related conditions like hypogonadism in human subjects.
USPTO Patent Application: Orally Disintegrating Corticosteroid Tablets for GI Inflammation
The USPTO has published a patent application (US20260083754A1) for orally disintegrating corticosteroid tablet compositions designed to treat gastrointestinal inflammation, specifically eosinophilic esophagitis. The application details the use of topically acting corticosteroids adsorbed onto a pharmaceutically acceptable carrier.
USPTO Patent Application: Upadacitinib Pharmaceutical Composition
The USPTO has published a new patent application (US20260083732A1) detailing a pharmaceutical composition for upadacitinib. The application, filed on September 6, 2023, describes a formulation involving upadacitinib, a hydrophobic release-controlling polymer, a pH modifier, and other excipients.
Uveal Melanoma Treatment Patent Application
The USPTO has published a patent application (US20260083731A1) detailing methods for treating uveal melanoma using a PKC inhibitor. The application, filed on August 25, 2023, by inventors Matthew Anthony Maurer, Michael Gabriel O'Quigley, and Julie Hambleton, focuses on neoadjuvant and/or adjuvant therapy to reduce metastasis and preserve eye function.
USPTO Patent Application for Metabolic Syndrome Treatment
The USPTO has published a patent application (US20260083753A1) for compositions and methods to treat metabolic syndrome. The application, filed by Kotha Sekharam, details improved compositions with enhanced solubility and bioavailability.
Patent Application: Cancer Treatment Methods and Compositions
The USPTO has published a patent application (US20260083752A1) for methods and compositions for treating cancer. The application, filed by the Regents of the University of Minnesota, involves the combination of p300/CBP modulators with senotherapeutics.
USPTO Patent Application: Allosteric Modulators for CRPC Therapy
The USPTO has published a patent application (US20260083751A1) from the University of Pittsburgh detailing allosteric modulators of the androgen receptor for treating castration-resistant prostate cancer (CRPC). The application describes small molecule compounds that may inhibit androgen receptor coactivator recruitment.
USPTO Patent Application: Dapiprazole for Eye Disorders
The USPTO has published a patent application (US20260083730A1) for a method of treating eye disorders using dapiprazole. The application, filed by Baradaina LLC, details a liquid composition for treating conditions such as presbyopia, glaucoma, or halos and glare.
USPTO Patent Application: Small Molecule Inhibitors of KRAS Proteins for Cancer Treatment
The USPTO has published a patent application (US20260083750A1) detailing small molecule inhibitors of KRAS proteins for cancer treatment. The application describes compounds that can inhibit specific KRAS protein mutants and their potential utility as therapeutic agents for cancer.
USPTO Patent for Anti-CD123 Immunoconjugates Treating AML
The USPTO has published a patent application (US20260083749A1) for anti-CD123 immunoconjugates, such as pivekimab sunirine, for treating acute myeloid leukemia (AML). The patent covers methods of use as monotherapies or in combination with other agents to achieve remission or prepare patients for transplant.
USPTO Patent Application: Compositions for Mitochondrial Health
The USPTO has published a patent application (US20260083747A1) detailing compositions for supporting mitochondrial health using methylthioninium salts combined with other compounds. The application was filed on October 30, 2024, by inventors Darren Lopez and Dan Schmidt.
USPTO Patent Application: Methods for Increasing Hematopoietic Stem Cells
The USPTO has published a patent application from Imago Biosciences, Inc. detailing methods for increasing hematopoietic stem cells and treating bone marrow failure using an LSD1 inhibitor. The application was filed on December 15, 2023, and published as US20260083729A1.
Reduced Dosing Regimens for Glaucoma Treatment Methods
The USPTO has published a patent application (US20260083746A1) detailing methods for treating open-angle glaucoma by transitioning patients to a once-daily dosing regimen. The proposed treatment involves a pharmaceutical composition containing timolol, brimonidine, dorzolamide, and bimatoprost.
USPTO Patent Application for Visual Pathway Strengthening Methods
The USPTO has published a new patent application (US20260083744A1) for methods of treating visual impairment by strengthening visual pathways. The application was filed on September 26, 2025, by inventors Ming-Fai Fong and Robert D. Lamprecht.
USPTO Patent Application: Compounds for Treating Parasitic Protozoa Infections
The USPTO has published a new patent application (US20260083728A1) detailing compounds for treating infections caused by parasitic protozoa, specifically Leishmania or Trypanosoma. The application was filed on September 18, 2023, by inventors from Karl WERBOVETZ et al.
USPTO Publishes Antiseptic Wipes Patent Application
The USPTO published a patent application for antiseptic wipes on March 26, 2026. The application details a cleansing composition including an antiseptic, humectant, emollient, surfactant, and monohydric alcohol, designed for use on a cloth. The invention also covers methods of preparing and packaging the wipes.
USPTO Patent Application: Nucleoside Derivative for Inflammation Treatment
The USPTO has published a patent application (US20260083743A1) detailing a nucleoside derivative for preventing and treating inflammation. The application, filed by WEST CHINA HOSPITAL OF SICHUAN UNIVERSITY, claims the derivative offers better efficacy and fewer side effects than existing treatments like indometacin.
Patent Application for Cancer Treatment with Azenosertib and HRD Biomarker
The USPTO has published a patent application (US20260083742A1) detailing methods for treating cancer by administering azenosertib to subjects selected based on homologous recombination repair deficiency (HRD). The application was filed on December 1, 2025.
Sotorasib Dosing Regimen Patent Application
The USPTO has received a patent application (US20260083741A1) for a sotorasib dosing regimen. The application, filed by Brett E. Houk and Panli Cardona, details methods for administering sotorasib to patients, particularly those with KRAS G12C-mutated cancer who also require treatment with a BCRP substrate like rosuvastatin.
USPTO Patent Application: Dental Composition Production Method
The USPTO has published a patent application (US20260083644A1) detailing a method for producing dental polymerizable compositions or intermediates with improved storage stability. The method involves specific steps for disposing and operating a composition within a container to achieve high yield and stability.
USPTO Patent Application: Dietary Compositions for Health and Diabetes Treatment
The USPTO has published a patent application (US20260083739A1) for dietary compositions containing minerals and vitamins, intended for various health benefits including diabetes treatment, improved athletic performance, and immune support. The application was filed on December 2, 2025.
USPTO Patent Application: Modified Release Minoxidil for Hair Loss
The USPTO has published a patent application (US20260083738A1) detailing modified release minoxidil oral formulations for treating hair loss. The application, filed by Reid Waldman, describes compositions including minoxidil alone or with other active agents, and methods of treatment. This represents a new patent filing for a potential pharmaceutical product.
USPTO Patent Application: Method for Coloring Dental Ceramic
The USPTO has published a patent application detailing a method for coloring dental ceramic using a solution containing specific metal ions. The application, filed by inventors from Japan, describes a process involving contacting the dental ceramic with a coloring liquid where the difference between standard oxidation-reduction potentials of at least two metal ions is between 0.5 and 4.0.
USPTO Patent Application: Dental Composition with Stable Paste Properties
The USPTO has published a new patent application detailing a dental composition designed for stable paste properties. The invention focuses on a specific filler composition and its surface treatment to improve long-term storage stability for dental materials.
USPTO Patent Application: Modified Release Minoxidil Formulations
The USPTO has published a patent application (US20260083737A1) detailing modified release minoxidil oral formulations and methods for treating hair loss. The application describes pharmaceutical compositions containing minoxidil or its salts, potentially with other active agents, and includes methods for their administration and related kits.
USPTO Patent Application: GOAT Inhibitors for Substance Use Disorder
The USPTO has published a patent application (US20260083736A1) for ghrelin O-acyl transferase (GOAT) inhibitors intended for the treatment of substance use disorder, particularly in patients with high impulsivity. The application details compounds of general formula I and their use in treating opioid or stimulant use disorders.
USPTO Patent Application for ABHD6 Antagonist Drug
The USPTO has published a patent application filed by ONO Pharmaceutical Co., Ltd. for a novel ABHD6 antagonist drug. The application details a compound with potential therapeutic applications for diseases associated with ABHD6 activity.
Nexgrill Recalls Metal Wire Bristle Grill Brushes Due to Ingestion Hazard
Nexgrill is recalling over 10.2 million metal wire bristle grill brushes due to an ingestion hazard where bristles can detach and cause internal injuries. Consumers are advised to stop using the recalled brushes and contact Nexgrill for a refund.
Sunnyyes LED Mini Lights Recalled Due to Battery Ingestion Hazard
The CPSC announced the recall of approximately 26,000 Sunnyyes LED Mini Lights due to a battery ingestion hazard that violates mandatory standards for consumer products with coin batteries. The recalled lights contain easily accessible lithium coin batteries and lack required warnings, posing a serious risk of injury or death to children.
DuraTrac Recalls Stainless Steel Gas Connectors Due to Fire Hazard
DuraTrac is recalling approximately 196,800 stainless steel gas connectors due to a manufacturing defect that could cause a gas leak and fire hazard. The recall affects connectors sold between May 2025 and November 2025. Consumers are advised to stop using the product immediately and contact DuraTrac for a full refund.
AirClub Convertible Bassinets Recalled for Fall Hazard
The CPSC announced the recall of approximately 110,400 AirClub Convertible Bassinets due to a fall hazard that violates the mandatory standard for bedside sleepers. The product creates an unsafe opening between the bassinet and an adult bed, posing a risk of serious injury or death to infants.
Vive Health Recalls Bed Rails Due to Entrapment and Death Risk
Vive Health is recalling approximately 122,000 adult portable bed rails due to a risk of serious injury or death from entrapment and asphyxiation. Two deaths have been reported in connection with one model of the recalled bed rails. Consumers are advised to stop using the products immediately and contact Vive Health for a full refund.
4our Kiddies Tip Restraint Kits Recalled Due to Tip-Over Hazard
The CPSC announced the recall of approximately 253,500 4our Kiddies Plastic Tip Restraint Kits due to a tip-over and entrapment hazard. The plastic components can break or degrade, posing a risk of serious injury or death. Consumers are advised to stop using the product immediately and contact the manufacturer for a replacement.
MPINOI Bed Rails Recalled Due to Entrapment and Asphyxiation Risk
The CPSC announced the recall of approximately 200 MPINOI Adult Portable Bed Rails due to a risk of entrapment and asphyxiation, violating mandatory safety standards. The product was sold on Amazon.com.
DIY Cold Plunge Sauna Heater Kits Recalled Due to Fire Hazard
The CPSC announced a recall of approximately 675 DIY Cold Plunge Sauna Heater Kits due to a fire hazard caused by overheating electrical conductors. Consumers are advised to stop using the product immediately and register for a full refund.
FUNTOK Ride-On Trucks Recalled for Fire and Burn Hazards
The CPSC announced the recall of approximately 1,980 FUNTOK 24V 2-Seater Ride-On Trucks due to a circuit board that can overheat and ignite, posing fire and burn hazards. Shenzhen Luobei Trading Co. is offering a full refund to consumers who disable the product.
Petzl America Recalls Ice Axes Due to Fall Hazard
Petzl America is recalling approximately 4,200 Nomic and Ergonomic ice climbing axes due to a fall hazard. The shafts can break during use, posing a risk of serious injury or death. Consumers should stop using the axes and contact Petzl for a free repair kit.
CCCEI Power Strips Recalled Due to Fire Risk
The CPSC announced the recall of approximately 5,543 CCCEI-branded power strips due to a fire risk caused by a lack of supplementary overcurrent protection. Consumers are advised to stop using the product immediately and contact Middle Way Electronics for a full refund. Two reports of sparking and melting have been received, but no fires or injuries have been reported.
GLMZZ Fidget Magnet Ball Toys Recalled Due to Ingestion Hazard
The CPSC announced the recall of approximately 9,350 GLMZZ Fidget Magnet Ball Toy Sets due to an ingestion hazard. The toys violate the mandatory standard for toys because they are high-powered magnets, posing a serious risk of injury or death if swallowed by children. Consumers are instructed to stop using the toys and contact GLMZZ for a full refund.
CMS Seeks Public Comment on Information Collection Activities
The Centers for Medicare & Medicaid Services (CMS) is seeking public comment on its intention to collect information from the public, as required by the Paperwork Reduction Act. This notice provides an opportunity for comment on the burden estimate and utility of proposed information collections related to Qualified Health Plan (QHP) certification and financial management.
DEA: Mississippi Meth Dealer Sentenced to 10 Years
The DEA announced the sentencing of Anthony Russell, a Mississippi meth dealer, to 10 years in prison. This action is highlighted as a victory for public safety and the agency's mission to combat drug trafficking, particularly fentanyl.
Apixaban Tablets Defect Notification - MHRA
The MHRA has issued a defect notification for Sandoz Limited's Apixaban 2.5mg and 5mg tablets. Certain batches have been distributed with Patient Information Leaflets that lack up-to-date information regarding paediatric indications and post-catheter removal guidance. Affected batches will continue to be distributed without repackaging.
Vesomni Tablets Defect Notification - Incorrect Barcode
The MHRA issued a Class 4 Medicines Defect Notification regarding Quadrant Pharmaceuticals Limited's Vesomni 6 mg/0.4 mg modified release tablets. The parallel imported packs have an incorrect barcode/GTIN on the carton, but the product quality is unaffected. No recall is issued, and patients do not need to take action.
MHRA and HSA Collaborate on Healthcare Regulatory Innovation
The MHRA and Singapore's HSA have refreshed a Memorandum of Understanding to collaborate on healthcare regulatory innovation, focusing on emerging technologies like AI and advanced therapies. This partnership aims to accelerate patient access to innovative treatments while maintaining safety and trust through initiatives like work-sharing and a new Regulatory Innovation Corridor pilot.
USPTO Patent Application: CD70 Antibody Drug Conjugates
The USPTO has published a new patent application (US20260083853A1) detailing CD70 antibody drug conjugates for treating cancer and autoimmune diseases. The application was filed on October 25, 2023, by inventors Xiao Shang and others.
USPTO Patent Application: Antibody Drug Conjugate Comprising NMT Inhibitor
The USPTO has published a new patent application (US20260083858A1) related to antibody drug conjugates (ADCs) that comprise an NMT inhibitor conjugated to an antibody via a linker. The application details the inventors and abstract of the invention.
USPTO Patent Application for Anti-PD-1 Antibody-IL-2 Immunoconjugate Formulations
The USPTO has published a new patent application (US20260083857A1) for anti-PD-1 antibody-IL-2 immunoconjugate formulations. The application details stable pharmaceutical formulations comprising anti-human PD-1 antibody-modified human interleukin-2 immunoconjugates.
USPTO Patent Application: IL-17 Antibody Compositions
The USPTO has published a patent application (US20260083842A1) detailing pharmaceutical products and stable liquid compositions of IL-17 antibodies, such as secukinumab. The application covers methods of making these compositions and their use in treating IL-17-mediated disorders, including autoimmune conditions like psoriasis and rheumatoid arthritis.
Bispecific Molecule Stabilizing Composition Patent Application
The USPTO has published a patent application (US20260083841A1) for a pharmaceutical composition designed to stabilize bispecific antigen-binding molecules at increased concentrations. The composition includes buffer agents, saccharides, and specific stabilizing agents like EDTA or citric acid.
USPTO Patent Application: NEO-201 Antibody for Suppressing Myeloid Derived Suppressor Cells
The USPTO has published a patent application (US20260083840A1) detailing methods for ablating myeloid derived suppressor cells using the NEO-201 antibody. The application describes the antibody's specific binding to certain O-glycans and its potential use in treating cancers and infectious diseases by suppressing gMDSCs.
USPTO Patent Application: Treating NSCLC with Dostarlimab or Biosimilar
The USPTO has published a patent application detailing a method for treating non-small cell lung cancer (NSCLC) using dostarlimab or a biosimilar. The application outlines a treatment approach for patients previously treated with an immune checkpoint inhibitor.
USPTO Patent Application: Modified Coronavirus Spike Antigen Protein
The USPTO has published a patent application (US20260083836A1) for a modified coronavirus spike antigen protein. The application describes a protein designed to suppress cell membrane fusion ability and improve safety by modifying cleavage sites, aiming to enhance vaccine efficacy and antibody production.
USPTO Patent Application: Phage T4 Nanoparticle Vaccine Platform
The USPTO has published a patent application (US20260083835A1) detailing a modular bacteriophage T4 nanoparticle vaccine platform. This platform is designed for the rapid development of dual COVID-19 and flu mucosal vaccines, administered intranasally without an adjuvant.
USPTO Patent Application for CsgA-Derived Nanostructures for Antigen Delivery
The USPTO has published a patent application (US20260083834A1) for CsgA-derived nanostructures designed for antigen delivery. The application details self-assembling polypeptides conjugated to immunogens that form nanofilaments to stimulate immune responses, potentially for vaccines against various conditions.
USPTO Patent Application: Engineered Probiotics Expressing Anti-Inflammatory Molecules
The USPTO has published a patent application (US20260083783A1) from the University of Cincinnati for engineered probiotics that express anti-inflammatory molecules. The application details a genetically modified E. coli bacterium designed to produce a microbial anti-inflammatory molecule (MAM) protein.
USPTO Patent Application for Generating CD4 T Cells
The USPTO has published a patent application (US20260083778A1) for methods of generating CD4 T cells from progenitor cells. The application, assigned to Boston Medical Center Corporation, describes a specific differentiation process for therapeutic use.
USPTO Patent Application: CARs for Hidradenitis Suppurativa Treatment
The USPTO has published a patent application (US20260083777A1) filed by Sonoma Biotherapeutics, Inc. The application describes chimeric antigen receptors (CARs) designed to target citrullinated polypeptides for the treatment of hidradenitis suppurativa.
USPTO Patent Application: Cancer Treatment with Anti-CD20 Antibody and Acylfulvenes
The USPTO has published a patent application (US20260083691A1) filed by Lantern Pharma Inc. The application describes a method for treating cancer by combining an anti-CD20 antibody with acylfulvenes. This patent application is related to novel therapeutic combinations for B-cell cancers.
USPTO Patent Application: Thiazolidine Linkers for Protein-Drug Conjugates
The USPTO has published a new patent application (US20260083856A1) detailing thiazolidine linkers for protein-drug conjugates and their uses in treating diseases. The application was filed on September 11, 2025, and is scheduled for publication on March 26, 2026.
USPTO Patent Application: Anti-DPP3 Antibody Formulations
The USPTO has published a patent application from 4TEEN4 Pharmaceuticals GmbH for formulations and dosage amounts for administering an anti-DPP3 antibody or fragment thereof to humans. The application, filed on August 26, 2025, details potential treatments for life-threatening circulatory failure conditions such as shock.
USPTO Patent Application: Recombinant Human Type III Collagen for Angiogenesis
The USPTO has published a patent application (US20260083883A1) detailing recombinant human type III collagen designed to promote angiogenesis. The application describes modifications to natural type III collagen to enhance its angiogenic function and adhesion properties, potentially increasing the angiogenesis rate by over 37%.
USPTO Patent Application: Compositions Targeting Endothelial Cells
The USPTO has published a patent application from Harvard College detailing novel compositions for targeting endothelial cells. These compositions, which include binders, linkers, and radioactive isotopes, are intended for selective delivery to cells and treating diseases, including cancer.
USPTO Patent Application: Sustained Transgene Expression of Modified ERT2 Peptide Fusion
The USPTO has published a patent application (US20260083859A1) detailing a novel fusion polypeptide for sustained transgene expression. The application, filed by inventors from various institutions, describes targeting constructs for inducible cell death systems using modified estrogen receptor ligand binding domains.
USPTO Patent Application for Capsid Polypeptides
The USPTO has published a new patent application (US20260083863A1) from Dyno Therapeutics, Inc. for capsid polypeptides designed for payload delivery. The application details specific polypeptide sequences and their methods of use in therapeutic applications.
USPTO Patent Application for Immunoconjugates
The USPTO has published a new patent application, US20260083855A1, filed by Hoffmann-La Roche Inc. The application relates to immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. This filing is part of the standard patent application process.
USPTO Patent Application: Antibody Conjugates with Bis-MSPT Linker
The USPTO has published a new patent application (US20260083854A1) detailing antibody conjugates that utilize a bis-MSPT linker. The application, filed by inventors Riazul Alam, Guillermo S. Cortez, and Yan Wang, describes pharmaceutical compositions and methods related to these conjugates.
USPTO Patent Application for Peptoid Nucleic Acid Delivery
The USPTO has published a patent application (US20260083769A1) detailing novel hydroxyalkyl-capped cationic peptoids for nucleic acid delivery. The application, filed by inventors from various institutions, describes compositions and methods for delivering polyanionic compounds to cells and eliciting immune responses.
Federal Mine Safety and Health Review Commission Sunshine Act Meetings Notice
The Federal Mine Safety and Health Review Commission has issued a notice regarding upcoming Sunshine Act meetings. This notice provides details on meeting schedules and any changes to previously announced times or locations.
ECHA Supports PFAS Restriction with Targeted Derogations
ECHA's scientific committees support an EU-wide restriction on per- and polyfluoroalkyl substances (PFAS). The restriction includes targeted derogations and controls to mitigate the risks these substances pose to human health and the environment. This action aligns with REACH regulations.
Lamotrigine Salts, Co-crystals, and Compositions Patent Application
The USPTO has published a patent application (US20260083745A1) for lamotrigine oral suspension and its preparation method, filed by Azurity Pharmaceuticals Ireland Limited. The application details a formulation designed to improve the stability and redispersibility of lamotrigine suspensions.
Patent Application: 7-Cyano-8-Hydroxyquinoline Derivative Medical Use
The USPTO has published a patent application for a 7-cyano-8-hydroxyquinoline derivative, its preparation method, and its medical use in treating infectious diseases or cancer. The application details a compound with potential antibacterial, antiviral, and antitumor activity.
TANF and MOE Annual Report Submission for OMB Review
The Administration for Children and Families (ACF) is requesting a 3-year extension for the Annual TANF and MOE Report (OMB #0970-0248). While no substantive changes are made to the form itself, the instructions have been updated, and burden estimates adjusted. This action supports GAO recommendations for enhanced oversight of TANF funds.
DEA: SpecGx LLC Controlled Substances Manufacturer Application
The Drug Enforcement Administration (DEA) has published a notice regarding an application from SpecGx LLC to be registered as a bulk manufacturer of various controlled substances, including Schedule I and II drugs. The notice provides a comment period for interested parties to submit objections or requests for a hearing.
CMS Seeks Public Comment on Information Collection Activities
The Centers for Medicare & Medicaid Services (CMS) has published a notice requesting public comment on its intention to collect information from the public. This action is part of the process under the Paperwork Reduction Act of 1995, requiring agency submissions for review and approval by the Office of Management and Budget (OMB).
CMS Launches ASPIRE Model for Medicaid Children's Care
The Centers for Medicare & Medicaid Services (CMS) has launched the ASPIRE model to improve care coordination for Medicaid children and families. The AMA welcomed the initiative, which aims to connect physicians with broader networks and support better management of chronic conditions for vulnerable populations.
Iowa Board of Pharmacy Adopts UMPJE Exam, Updates PMP Access
The Iowa Board of Pharmacy announced the adoption of the Uniform Multistate Pharmacy Jurisprudence Exam (UMPJE) effective April 1, 2026, and updated access policies for its Prescription Management Program (PMP). Pharmacist access to the Rx Management tool is now restricted to those with a DEA registration number, and data submissions missing a prescriber's DEA number will be flagged as errors.
Iowa Board of Pharmacy Newsletter: Rule Delays, MPJE Update, New Board Members
The Iowa Board of Pharmacy announced a 70-day administrative delay for adopted rules that would have rescinded and created new chapters in the Iowa Administrative Code. Despite this delay, the Multistate Pharmacy Jurisprudence Examination (MPJE) content will reflect the new rules effective August 1, 2025, to prepare new graduates and out-of-state pharmacists for eventual implementation.
Iowa Board of Pharmacy Newsletter October 2025
The Iowa Board of Pharmacy newsletter for October 2025 announces new board members and updates on expanded authority for statewide protocol development. It also details changes to business license application processes allowing retention of existing license numbers and notes that Long-Term Care Facilities and Assisted Living Facilities no longer require CSA registration.
Iowa Board of Pharmacy Newsletter: Rule Review and PMP Changes
The April 2025 Pharma Phacts newsletter from the Iowa Board of Pharmacy details ongoing administrative rule reviews mandated by Executive Order 10. Two chapters have been republished under Amended Notices of Intended Action following public comment, with a comment period closing March 25, 2025. The newsletter also notes the Board of Pharmacy rules are moving to Agency ID 481 under the Department of Inspections, Appeals, and Licensing (DIAL).
KS Boards of Pharmacy and Healing Arts Joint Statement on IV Therapy Clinics
The Kansas Boards of Pharmacy and Healing Arts have issued a joint statement addressing concerns about patient safety and regulatory compliance in retail IV therapy clinics. The statement clarifies that IV therapy is a medical practice requiring licensed professionals and outlines the Boards' investigative and referral processes for complaints.
KS Board of Pharmacy: Proposed Regulation Changes and Updates
The Kansas Board of Pharmacy is proposing changes to administrative regulations, including K.A.R. 68-5-17 and 68-7-26, and revoking K.A.R. 68-1-1a. The newsletter also reminds pharmacists and technicians about free CE on PMP data integrity and requests feedback on USP <797> and <795> adoption.
Kansas Pharmacy Technician Renewal Deadline and Requirements
The Kansas Board of Pharmacy has issued a newsletter reminding pharmacy technicians of the October 31, 2025 renewal deadline. Technicians must complete 20 hours of continuing education and can request a six-month extension if they cannot pass the certification exam by the deadline. Failure to renew will result in registration cancellation and requires a new application process.
Kansas Board of Pharmacy Named 2025 Wellbeing First Champion
The Kansas Board of Pharmacy has been recognized as a 2025 Wellbeing First Champion for removing stigmatizing language from its licensing and renewal applications related to mental health. The Board is also initiating a stakeholder process to solicit feedback on its rules and regulations, with submissions due by October 31, 2025.
Kansas Adopts Uniform MPJE for Pharmacist Licensure
The Kansas Board of Pharmacy has adopted the Uniform Multistate Pharmacy Jurisprudence Examination (MPJE) for pharmacist licensure, effective April 1, 2026. New graduates and pharmacists transferring licenses will be required to pass the Uniform MPJE, with the previous Kansas MPJE being discontinued at the end of 2026.
National Eye Institute Announces Closed Meeting Notice
The National Institutes of Health has issued a notice announcing a closed meeting of the Board of Scientific Counselors, National Eye Institute. The meeting will be held virtually on April 6, 2026, to review and evaluate individual intramural programs, personnel qualifications, and investigator performance.
FDA Correction: Withdrawal of 72 ANDAs - Upsher-Smith Laboratories
The FDA issued a correction to a notice that incorrectly announced the withdrawal of approval for Upsher-Smith Laboratories' abbreviated new drug application (ANDA) 070631 for valproic acid capsules. The company had timely requested that the approval not be withdrawn, and this correction reinstates its validity.
FDA Complaint Filed
The Food and Drug Administration (FDA) has filed a complaint related to tobacco products. The comment period for this filing has closed. No further details on the nature of the complaint or specific parties involved are available in the provided information.
FDA Complaint Posted
The FDA has posted a complaint related to its regulations, with the comment period closing on March 25, 2026. The document is available for review on Regs.gov.
USPTO Letter to FDA CDER
The U.S. Patent and Trademark Office (USPTO) sent a letter to the FDA's Center for Drug Evaluation and Research (CDER). The document was posted on March 25, 2025, via Regs.gov. No content is available for viewing or download, only metadata about the letter.
Patent Office Letter to FDA CDER
The FDA has posted a letter from the U.S. Patent and Trademark Office addressed to the FDA's Center for Drug Evaluation and Research (CDER). The document is available for review on Regulations.gov.
USPTO Letter to FDA CDER
The U.S. Patent and Trademark Office (USPTO) has sent a letter to the FDA's Center for Drug Evaluation and Research (CDER). The document is a notification, and no specific regulatory action or compliance requirement is detailed within the available information.
USPTO Letter to FDA CDER
The U.S. Patent and Trademark Office (USPTO) has sent a letter to the FDA's Center for Drug Evaluation and Research (CDER). The document is available on Regs.gov, but no content or specific details of the letter's subject matter are provided.
Letter from U.S. Patent Office to FDA CDER
The FDA has posted a letter received from the U.S. Patent and Trademark Office addressed to the FDA's Center for Drug Evaluation and Research (CDER). The document is available for review on Regulations.gov.
FDA Complaint Filed and Closed for Comments
The FDA has filed a complaint related to tobacco products, with the comment period now closed. The specific details of the complaint and the affected parties are not available in the provided document.
Letter from USPTO to FDA CDER
The U.S. Patent and Trademark Office (USPTO) has sent a letter to the FDA's Center for Drug Evaluation and Research (CDER). The document is available for review on Regulations.gov, though no content is directly viewable within the portal.
FDA Complaint Filed
The FDA has posted a complaint filed on March 25, 2026. The complaint was authored by CTP and is now closed for comments. No documents are available for viewing or download.
FDA Completeness Assessment Correspondence
The FDA has posted Completeness Assessment Correspondence related to drug applications. This notice provides information from the Center for Drug Evaluation and Research (CDER) regarding the completeness of submitted applications.
Letter from U.S. Patent Office to FDA CDER
The FDA's Center for Drug Evaluation and Research (CDER) has posted a letter received from the U.S. Patent and Trademark Office. The document is dated March 25, 2026, and is available for review on Regulations.gov.
FDA Complaint Posted
The FDA has posted a complaint on March 25, 2026, which was closed for comments. The complaint document is available for download from the agency's regulations.gov portal.
FDA CDER Letter from U.S. Patent and Trademark Office
The FDA has posted a letter from the U.S. Patent and Trademark Office to its Center for Drug Evaluation and Research (CDER). The document is dated March 25, 2026, and is available for review on Regs.gov.
FDA CDER Receives Letter from U.S. Patent Office
The FDA's Center for Drug Evaluation and Research (CDER) has received a letter from the U.S. Patent and Trademark Office. The document is available for review on Regulations.gov, though no specific content is provided in the listing.
USPTO Letter to FDA CDER
The U.S. Patent and Trademark Office (USPTO) sent a letter to the FDA's Center for Drug Evaluation and Research (CDER). The document was posted on March 25, 2024, via Regulations.gov. No specific details or content of the letter are available.
FDA Complaint Document
The FDA has posted a complaint document related to its Center for Tobacco Products (CTP). The document is available for review on Regulations.gov, though no specific details of the complaint are provided in the notice.
FDA Complaint Document
The FDA has posted a complaint document, FDA-2026-H-2883-0001, on March 25, 2026. The document is available via a link to regulations.gov, though no content is directly viewable or downloadable from the initial posting.
FDA Variance Renewal Request from Shine On Floyd Band
The Food and Drug Administration (FDA) has received a variance renewal request from Shine On Floyd Band. The document is available for review on regulations.gov, though no specific details or content are provided within the listing itself.
FDA Complaint Document
The FDA has posted a complaint document related to FDA-2026-H-2608. The document is available for review, though no specific details about its content are provided in the initial posting. This notice serves to inform the public and relevant parties of the complaint's availability.
FDA Approves Avlayah for Neurologic Manifestations of Hunter Syndrome
The FDA has approved Avlayah (tividenofusp alfa-eknm) for the treatment of neurologic manifestations of Hunter syndrome in certain pediatric patients. This marks the first drug approval specifically targeting the neurological complications of this rare genetic disorder.
USDA FSIS Public Health Alert for Beef and Pork Products
The USDA's Food Safety and Inspection Service (FSIS) has issued a public health alert for beef and pork products that were produced without the benefit of inspection. This alert is being issued due to concerns about potential contamination and the lack of federal oversight during production.
Health Canada Seizes Unauthorized Counterfeit Health Products in Mississauga
Health Canada issued a public advisory regarding the seizure of unauthorized and counterfeit health products, including prescription drugs and injectables, from a Mississauga location. These products have not been assessed for safety, efficacy, or quality and pose serious health risks.